Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice

Radiation Oncology Investigations

Volumn 5, Issue 5, 1997, Pages 213-219

  Durand, Ralph E ^a   Olive, Peggy L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Blood flow; Hypoxia; Radiation; Tirapazamine

Indexed keywords

CELL DNA; HOE 33342; TIRAPAZAMINE;

AEROBIC CAPACITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; HYPOXIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SPHEROID CELL; TUMOR BLOOD FLOW; TUMOR XENOGRAFT; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL SEPARATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TRIAZINES;

EID: 0030669672     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1997)5:5<213::AID-ROI1>3.0.CO;2-0     Document Type: Article

References (30)

1. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WE: SR 4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986.
2. Durand RE, Olive PL: Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 22:689-692, 1992.
3. Durand RE: The influence of microenvironmental factors during cancer therapy. In Vivo 8:691-702, 1994.
4. Olive PL: Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br J Cancer 71:529-536, 1995.
5. Brown JM: SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993.
6. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955.
7. Chaplin DJ, Durand RE, Olive PL: Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer 51:569-572, 1985.
8. Chaplin DJ, Olive PL, Durand RE: Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 47:597-601, 1987.
9. Coleman CN: Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. JNCI 80:310-317, 1988.
10. Durand RE, LePard NE: Modulation of tumor hypoxia by conventional chemotherapeutic agents. Int J Radiat Oncol Biol Phys 29:481-486, 1994.
11. Olive PL, Banáth JP, Durand RE: Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 122:86-94, 1990.
12. Durand RE, LePard NE: Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol 34:317-324, 1995.
13. Friedl F, Kimura I, Osato T, Ito Y: Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med 135:543-545, 1970.
14. Olive PL: Distribution, oxygenation and clonogenicity of macrophages in a murine tumor. Cancer Comm 1: 93-100, 1989.
15. Durand RE: Use of a cell sorter for assays of cell clonogenicity. Cancer Res 46:2775-2778, 1986.
16. Sutherland RM, Durand RE: Radiation response of multicell spheroids-An in vitro tumour model. Curr Topics Radiat Res Q 11:87-139, 1976.
17. Trotter MJ, Chaplin DJ, Durand RE, Olive PL: The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 16:931-934, 1989.
18. Durand RE, LePard NE: Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother Oncol 42:171-179, 1997.
19. Olive PL, Vikse CM, Banáth JP: Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice. Cancer Res 56:4460-4463, 1996.
20. Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745-7749, 1990.
21. Kim IH, Brown JM: Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29:493-497, 1994.
22. Olive PL, Chaplin DJ, Durand RE: Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumors. Br J Cancer 52:739-746, 1985.
23. Chaplin DJ, Durand RE, Olive PL: Acute hypoxia in tumors: Implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 12:1279-1282, 1986.
24. Chaplin DJ, Trotter MJ, Durand RE, Olive PL, Minchinton AI: Evidence for intermittent radiobiological hypoxia in experimental tumour systems. Biomed Biochem Acta 48:255-259, 1989.
25. Koch CJ: Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53:3992-3997, 1993.
26. Senan S: Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation. Int J Radiat Oncol Biol Phys 31:209-210, 1995.
27. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR: Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimeihylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29:373-377, 1994.
28. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S, Roemeling RV: Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 29:379-382, 1994.
29. Dorie MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993.
30. Langmuir VK, Rooker JA, Osen M, Mendonca HL, Laderoute KR: Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54:2845-2847, 1994.